טוען...

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy

INTRODUCTION: Emtricitabine/rilpivirine/tenofovir (EVP) is a fixed-dose combination of antiretrovirals (ARV) approved by the European Medicines Agency in November 2011 and introduced in Italy in February 2013. It is a once-a-day single tablet and is licensed in Europe for use only in ARV-naïve patie...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Int AIDS Soc
Main Authors: Cozzi-Lepri, Alessandro, Lo Caputo, Sergio, Maggiolo, Franco, Antinori, Andrea, Ammassari, Adriana, Marchetti, Giulia, Mastroianni, Claudio, Gori, Andrea, Di Perri, Giovanni, Angarano, Gioacchino, Carbone, Alessia, d'Arminio Monforte, Antonella
פורמט: Artigo
שפה:Inglês
יצא לאור: International AIDS Society 2014
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225399/
https://ncbi.nlm.nih.gov/pubmed/25397519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19775
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!